Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate

Authors: Liangdong Jiang, Cheng Tao, Aiyong He, Xiaojie He

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

miR-126 plays an important role in the proliferation, invasion, migration, and chemotherapeutics resistance in cancer. Epigallocatechin-3-gallate (EGCG), as the major polyphenolic constituent present in green tea, is a promising anticancer agent. However, the role of miR-126 in EGCG anticancer remains unclear. Here, we investigated the effects of miR-126 and EGCG on cell viability, apoptosis, cell cycle distribution of osteosarcoma cells and the sensitization of miR-126 on osteosarcoma cells to EGCG.

Methods

The cell viability, apoptosis and cycle distribution were analyzed using MTT assay and flow cytometry.

Results

Our results showed that EGCG (0.025, 0.05, 0.1, 0.2 g/L) suppresses proliferation of osteosarcoma MG63 and U2OS cells in a concentration-dependent and time-dependent manner and the inhibitory effects of 0.05 g/L EGCG on U2OS cells were roughly equivalent to 20 μM cisplatin (DDP); miR-126 could promote apoptosis and inhibit proliferation in U2OS cells but without significant effects on cell cycle G1 phase arrest; EGCG suppressed proliferation of U2OS cells through induction of cell cycle G1 arrest and apoptotic death; overexpression of miR-126 enhanced the inhibitory effects of EGCG on proliferation in U2OS cells via promotion of apoptosis.

Conclusions

Our results demonstrate that enhanced expression of miR-126 increased the sensitivity of osteosarcoma cells to EGCG through induction of apoptosis.
Appendix
Available only for authorised users
Literature
1.
Luetke A, Meyers PA, Lewis I, Juergens H: Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014, 40: 523-532. 10.1016/j.ctrv.2013.11.006.CrossRefPubMed
2.
Lambert JD, Sang S, Hong J, Yang CS: Anticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol, (-)-epigallocatechin-3-gallate. J Agric Food Chem. 2010, 58: 10016-10019. 10.1021/jf102311t.PubMedCentralCrossRefPubMed
3.
Kalaiselvi P, Rajashree K, Bharathi Priya L, Padma VV: Cytoprotective effect of epigallocatechin-3-gallate against deoxynivalenol-induced toxicity through anti-oxidative and anti-inflammatory mechanisms in HT-29 cells. Food Chem Toxicol. 2013, 56: 110-118.CrossRefPubMed
4.
Cheng CW, Shieh PC, Lin YC, Chen YJ, Lin YH, Kuo DH, Liu JY, Kao JY, Kao MC, Way TD: Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem. 2010, 58: 887-894. 10.1021/jf903377e.CrossRefPubMed
5.
Pae M, Wu D: Immunomodulating effects of epigallocatechin-3-gallate from green tea: mechanisms and applications. Food Funct. 2013, 4: 1287-1303. 10.1039/c3fo60076a.CrossRefPubMed
6.
Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I: Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 2013, 13: 632-637. 10.1166/jnn.2013.6882.CrossRefPubMed
7.
Ahn WS, Huh SW, Bae SM, Lee IP, Lee JM, Namkoong SE, Kim CK, Sin JI: A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. DNA Cell Biol. 2003, 22: 217-224. 10.1089/104454903321655846.CrossRefPubMed
8.
Deng YT, Lin JK: EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem. 2011, 59: 13318-13327. 10.1021/jf204149c.CrossRefPubMed
9.
Hsieh TC, Wu JM: Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res. 2009, 29: 4025-4032.PubMedCentralPubMed
10.
Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, Park OJ: Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett. 2007, 247: 115-121. 10.1016/j.canlet.2006.03.030.CrossRefPubMed
11.
Kang SU, Lee BS, Lee SH, Baek SJ, Shin YS, Kim CH: Expression of NSAID-activated gene-1 by EGCG in head and neck cancer: involvement of ATM-dependent p53 expression. J Nutr Biochem. 2013, 24: 986-999. 10.1016/j.jnutbio.2012.07.003.CrossRefPubMed
12.
Park JS, Khoi PN, Joo YE, Lee YH, Lang SA, Stoeltzing O, Jung YD: EGCG inhibits recepteur d’origine nantais expression by suppressing Egr-1 in gastric cancer cells. Int J Oncol. 2013, 42: 1120-1126.PubMed
13.
Trudel D, Labbe DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, Plante M, Gregoire J, Renaud MC, Bachvarov D, Têtu B, Bairati I: A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013, 131: 357-361. 10.1016/j.ygyno.2013.08.019.CrossRefPubMed
14.
Chen D, Pamu S, Cui Q, Chan TH, Dou QP: Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem. 2012, 20: 3031-3037. 10.1016/j.bmc.2012.03.002.PubMedCentralCrossRefPubMed
15.
Honicke AS, Ender SA, Radons J: Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells. Int J Oncol. 2012, 41: 753-758.PubMed
16.
Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, Wang Z, Wang Z, Cheng P, Tong D, Li C, Tang H: MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone. 2013, 56: 220-226. 10.1016/j.bone.2013.05.020.CrossRefPubMed
17.
Fan L, Wu Q, Xing X, Wei Y, Shao Z: MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin. 2012, 44: 407-414. 10.1093/abbs/gms019.CrossRefPubMed
18.
Han K, Zhao T, Chen X, Bian N, Yang T, Ma Q, Cai C, Fan Q, Zhou Y, Ma B: microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol. 2014, 45: 1437-1449.PubMedCentralPubMed
19.
Yang C, Hou C, Zhang H, Wang D, Ma Y, Zhang Y, Xu X, Bi Z, Geng S: miR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci. 2014, 15: 423-437.PubMedCentralCrossRef
20.
Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013, 8: e53906-10.1371/journal.pone.0053906.PubMedCentralCrossRefPubMed
21.
Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H, Xu W: miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin. 2012, 44: 519-526. 10.1093/abbs/gms026.CrossRefPubMed
22.
Yu Q, Liu SL, Wang H, Shi G, Yang P, Chen XL: miR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pac J Cancer Prev. 2013, 14: 6569-6572. 10.7314/APJCP.2013.14.11.6569.CrossRef
23.
Singh BN, Shankar S, Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011, 82: 1807-1821. 10.1016/j.bcp.2011.07.093.PubMedCentralCrossRefPubMed
24.
Xu X, Wells A, Padilla MT, Kato K, Kim KC, Lin Y: A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance. Carcinogenesis. 2014, 35: 2457-2466. 10.1093/carcin/bgu159.CrossRefPubMed
25.
Weng H, Huang H, Dong B, Zhao P, Zhou H, Qu L: Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res. 2014, 74: 4409-4419. 10.1158/0008-5472.CAN-13-1748.CrossRefPubMed
26.
Frampton AE, Krell J, Jacob J, Stebbing J, Castellano L, Jiao LR: Loss of miR-126 is crucial to pancreatic cancer progression. Expert Rev Anticancer Ther. 2012, 12: 881-884. 10.1586/era.12.67.CrossRefPubMed
27.
Liu LY, Wang W, Zhao LY, Guo B, Yang J, Zhao XG, Hou N, Ni L, Wang AY, Song TS, Huang C, Xu JR: Mir-126 inhibits growth of SGC-7901 cells by synergistically targeting the oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J Oncol. 2014, 45: 1257-1265.PubMed
28.
Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 1997, 89: 1881-1886. 10.1093/jnci/89.24.1881.CrossRefPubMed
29.
Gupta S, Hussain T, Mukhtar H: Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys. 2003, 410: 177-185. 10.1016/S0003-9861(02)00668-9.CrossRefPubMed
30.
Harakeh S, Abu-El-Ardat K, Diab-Assaf M, Niedzwiecki A, El-Sabban M, Rath M: Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and -negative leukemia cells. Med Oncol. 2008, 25: 30-39. 10.1007/s12032-007-0036-6.CrossRefPubMed
31.
Sui XQ, Xu ZM, Xie MB, Pei DA: Resveratrol inhibits hydrogen peroxide-induced apoptosis in endothelial cells via the activation of PI3K/Akt by miR-126. J Atheroscler Thromb. 2014, 21: 108-118. 10.5551/jat.19257.CrossRefPubMed
Metadata
Title
Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate
Authors
Liangdong Jiang
Cheng Tao
Aiyong He
Xiaojie He
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-383

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Research

Age trend of the male to female sex ratio in surgical gastric cancer patients at a single institution

Research

Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer

Research

Femur performed better than tibia in autologous transplantation during hemipelvis reconstruction

Case report

Multiple primary malignancies of the liver and the colon: a complex diagnostic and decisional process with a final unanswered question

Research

Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland

Research

Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients